Noticias de la Fundación del SPF

Los Datos Disponibles acerca de los Efectos Secundarios de la 5α-RIs No Sugieren de Forma Conclusiva que Sean Seguros, Dicen Investigadores de La Escuela de Medicina de la Universidad de Boston.

SOMERSET, N.J., Sept. 7, 2015 – Data from preclinical and clinical studies have provided substantial evidence that 5α-Reductase inhibitors (5α-RIs) such as finasteride and dutasteride cause loss or reduction of libido, increase the risk of erectile dysfunction and ejaculatory dysfunction, and may contribute to the onset of depression. These agents interfere with the biosynthesis and […]

La Sugerencia de que los Efectos Secundarios Sexuales que Aparecen al Principio en la Terapia con Finasterida Vuelven a la Normalidad Después es ‘Incorrecta,’ Dicen Investigadores de La Escuela de Medicina de la Universidad de Boston

SOMERSET, N.J., Aug. 26, 2015 – Twenty-five percent of men currently taking finasteride or dutasteride (brand names Proscar and Avodart) for the treatment of benign prostate enlargement (BPH), appear not to benefit from taking these medications. Those prescribed Propecia or Avodart for male pattern hair loss are also at risk for adverse events elicited by […]

Discurso Anual de la Fundación SPF 2015

Aug. 4, 2015 Dear Friends: By many accounts, we’ve reached a tipping point on post-finasteride syndrome awareness within the medical community. The most significant advancement occurred in March, when the U.S. National Institutes of Health added PFS to its Genetic and Rare Diseases Information Center. “Studies are under way to understand the safety profile of […]

Ideación Suicida Asociada con el Uso de Fiansterida en Jóvenes, Dice un Nuevo Estudio en una Importante Revista de Farmacología

SOMERSET, N.J., July 23, 2015 – New research in a leading pharmacology journal concludes that young men who take finasteride for hair loss may be at risk of contemplating suicide. The study, published in the July issue of Pharmacotherapy and titled “Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride,” analyzed […]

Institutos Nacionales de Salud de los EE.UU. Añaden el SPF al Centro de Información de Emfermedades Genéticas Raras

May 19, 2015 Dear Public Health Official: The U.S. National Institutes of Health recently added post-finasteride syndrome (PFS) to its Genetic and Rare Diseases Information Center, noting that: “Studies are underway to understand the safety profile of 5-alpha reductase inhibitor drugs with respect to adverse events…and their permanency.” This federal listing of PFS comes in […]

Un Estudio Clínico del Síndrome Post-Finasterida es Lanzado por la Universidad de Bicocca, Milán y la Universidad de Milán.

SOMERSET, N.J., Dec. 9, 2014 – The Post-Finasteride Syndrome Foundation today announced the funding of a third clinical study on post-finasteride syndrome (PFS), this one a collaboration between the University of Milano-Bicocca and the University of Milano, both in Italy. Titled “Rare, but Serious and Persistent, Side Effects of 5α Reductase Inhibitors (5ARI): Why Do […]

Discurso Anual de la Fundación SPF 2014

Aug. 4, 2014 Dear Friends: I’m pleased to report that 2014 is shaping up to be a turning point on the road to widespread awareness of post-finasteride syndrome. Couple that with the steady progress of our clinical studies and I become ever more hopeful that the coming year will bring not only worldwide acceptance of […]